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Artificial 64-residue HIV-1 enhancer-binding peptide is a
potent inhibitor of viral replication in HIV-1-infected cells
Abstract
An artificial HIV-1 enhancer-binding peptide was extended by nine consecutive arginine
residues at the C-terminus and by the nuclear localization signal of SV40 large T antigen at the
N-terminus. The resulting synthetic 64-residue peptide was found to bind to the two
enhancers of the HIV-1 long terminal repeat, cross the plasma membrane and the nuclear
envelope of human cells, and suppress the HIV-1 enhancer-controlled expression of a green
fluorescent protein reporter gene. Moreover, HIV-1 replication is inhibited by this peptide in
HIV-1-infected CEM-GFP cells as revealed by HIV-1 p24 ELISA and real-time RT-PCR of
HIV-1 RNA. Rapid uptake of this intracellular stable and inhibitory peptide into the cells
implies that this peptide may have the potential to attenuate HIV-1 replication in vivo.
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An artificial HIV-1 enhancer-binding peptide was extended by nine consecutive arginine residues at the C-terminus and by the
nuclear localization signal of SV40 large T antigen at the N-terminus. The resulting synthetic 64-residue peptide was found to bind
to the two enhancers of the HIV-1 long terminal repeat, cross the plasma membrane and the nuclear envelope of human cells, and
suppress the HIV-1 enhancer-controlled expression of a green fluorescent protein reporter gene. Moreover, HIV-1 replication is
inhibited by this peptide in HIV-1-infected CEM-GFP cells as revealed by HIV-1 p24 ELISA and real-time RT-PCR of HIV-1 RNA.
Rapid uptake of this intracellular stable and inhibitory peptide into the cells implies that this peptide may have the potential to
attenuate HIV-1 replication in vivo.
1. Introduction
Treatment of HIV-1 infection has made considerable
progress. Nevertheless, all current therapeutic approaches
have been hampered by viral resistance mutations, undesired
side effects, and high treatment cost [1].
Therefore, additional concepts for inhibiting HIV-1
replication, particle assembly, and escape have been devel-
oped.
One approach to interfere with HIV-1 infection at
an early stage is to block viral entry. Enfuvirtide, a syn-
thetic peptide already in clinical use corresponding to the
conserved extramembranous sequence 643 to 678 of the
HIV-1 envelope glycoprotein gp41, was found to prevent
the conformational change of gp41 necessary for HIV-1
fusion with CD4+ cells [2, 3]. Other approaches include the
construction of a highly colonizing Escherichia coli (E. coli)
strain secreting HIV-1 gp41-hemolysin to block HIV fusion
with target cells [4], the use of an interchain disulfide bond-
stabilized trimeric 45-residue fusion peptide [5, 6] to inhibit
the fusion of a large number of HIV isolates with target cells,
and the inhibition of HIV-1 infection of CD4+ T cells by
microbial HSP70 [7].
Similarly, the human monoclonal 5H/I1-BMV-D5
single-chain variable region fragment (scFv) antibody
selected from phage-displayed libraries has been shown to
bind to the N-terminal heptad repeat region of gp41 and
thus inhibited the formation of fusion intermediates in vitro
and the replication of diverse clinical isolates of HIV-1 [8].
In macaques, protection from vaginal challenge with simian
human immunodeficiency virus was achieved by vaginally
delivered inhibitors of virus-cell fusion; moreover, two small
molecule inhibitors binding to viral gp120 and cellular
CCR5, respectively, prevent receptor binding by gp120,
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and a 53-residue peptide containing the C-terminal heptad
repeat region of gp41 inhibited the gp41-mediated virus-cell
fusion [9].
However, HIV-1 particles interacting only weakly with
fusion inhibitors would still be able to enter target cells [10].
This requires other strategies to repress the viral replication
after the virus has invaded the target cells. These include
Highly Active AntiRetroviral Therapy (HAART) treatment
[1], the intracellular expression of an antisense gene targeting
the HIV-1 envelope [11] and the sequence-specific targeting
of the three Sp1 sites of the 5′-long terminal repeat (LTR)
of HIV-1 by engineered zinc-fingers [12]. In the present
work, we have designed a 64-residue protein that crossed
plasma and nuclear membranes, recognized the two highly
conserved NF-κB binding sites (enhancers) of the 5′-LTR of
HIV-1, and acted as a strong inhibitor of HIV-1 replication
in infected cells.
This synthetic 64-residue peptide (R64, Figure 1) con-
tained, from N- to C- terminus, the nuclear localization
signal of SV40 large T antigen, the recognition helix of
bacteriophage 434 repressor (residues 28 to 36) flanked at
both ends by two copies of the positively charged repressor
sequence 37 to 44 and nine arginine residues (Arg9) for
plasma membrane transduction [13]. The recognition helix
of 434 repressor was used because the nucleotide sequences
of the two enhancers in the 5′-LTR region of HIV-1
were identical to repressor-binding sequences of the 434
operators, and shorter versions of R64 lacking Arg9 [14] or
both the Arg9 and the NLS sequences (R42, [14, 15]) had
been shown to bind to the enhancer region of synthetic
HIV-1 LTR DNA, thereby displacing the p50 subunit of NF-
κB from its two binding sites in LTR and inhibiting HIV-1
enhancer-driven transcription [14, 15].
Despite their potential immunogenicity, therapeutic
peptides may play an important role as shown by their
application in the treatment of prostate cancer in mice
[16], in the prevention of HIV-1 infection [2, 3], and the
induction of Wilms’ tumor-gene-(WT1)-specific cytotoxic T
lymphocytes with resultant cancer regression in human [17].
Since covalently linked oligoarginine and related sequences
efficiently mediate membrane transduction of polypeptides
[18, 19], R64 and similar peptides could be very useful in a
combinatorial therapy against HIV-1 infection by targeting
the NF-κB-binding sites of the HIV-1 enhancers [20].
2. Materials and Methods
2.1. Synthesis and Purification of the Peptides. The 20 to 64
residues long peptides were synthesized by the solid-phase
method [22, 23] on an Applied Biosystems 430A peptide
synthesizer using Fmoc chemistry and following the instruc-
tions of the manufacturer. After deprotection and cleavage
from the resin, they were purified on an Agilent 1100 HPLC
system equipped with an autosampler, a diode array detector
and an Interchim Uptisphere C18 column (250 × 4.6mm).
The peptides were eluted with a solvent gradient from 0.1%
trifluoroacetic acid (TFA) to 0.075% TFA in acetonitrile. The
purity of the peptides was demonstrated by ion spray mass
spectrometry on a MALDI-TOF Bruker spectrometer and
their concentration determined by quantitative amino acid
analysis on a Biochrom 20 amino acid analyzer.
All synthetic oligodeoxyribonucleotides were purchased
from MicroSynth (Balgach, Switzerland).
2.2. Band Shift Assays of R64-HIV LTR Interactions. Assays
followed standard procedures [21, 25]. Binding reactions,
performed in triplicate with identical results, contained
R64 (Figure 1(b)), a synthetic 5′-end 32P-labeled 70-base
pair (bp) oligodeoxyribonucleotide (Figure 1(e)) enclos-
ing the two NF-κB-binding sequences (enhancers, under-
lined residues), and a synthetic 51-bp competitor DNA
(Figure 1(f)) in 20 μL phosphate buffer, pH 7.4 [26]. After
incubation for 30min at 37◦C, samples were analyzed by
10% polyacrylamide gel electrophoresis. After drying, the
radioactivity in the gel was analyzed by phosphoimaging
(Figure 2).
2.3. Footprint Assay of R64-HIV-1 Enhancer-Binding Speci-
ficity. The synthetic HIV LTR DNA (sequence shown in
Figure 3) comprised positions –118 to –67 including two
enhancer regions (Figure 3, vertical bars). The standard
footprint procedure [27] was modified as follows. R64 was
added to the labelled truncated HIV-1 LTR DNA and the
mixture submitted to gel electrophoresis. The bands of the
R64-DNA complex and of free DNA were excised, and
sterically available N-7 positions of the guanine bases were
methylated in the gel slices using dimethyl-sulfate [28].
After elution from the gel slices the DNA was cleaved at
the sites of methylation by 10% piperidine [24], and the
fragments formed were resolved by gel electrophoresis in a
buffer containing 90mM Tris-borate, pH 8.3, 25mM EDTA.
Dried gels were analyzed by phospho-imaging (Figure 3). In
parallel, sequencing of the labeled DNA by the method of
Maxam and Gilbert [24] allowed localization of the binding
sites of R64. The footprint assay was performed twice; the
patterns obtained were in very good agreement.
2.4. HIV-1 LTR-Controlled InVitro Transcription in the
Absence and Presence of R64. OVEC-LTR, the plasmid used
to test the activity of R64 in cell-free in vitro transcription,
contained the two NF-κB and the three specificity protein
1 (Sp1) binding sites (positions –110 to –45) of HIV-1
LTR and a β-globin reporter gene [14, 29]. As a control,
plasmid Sp1-OVEC contained only Sp1 binding sites and
lacked the first 19 base pairs of the β-globin gene [29].
Equal amounts of both plasmids were used (100 ng each) and
the protocol described previously was followed [14]. RNA
extraction, purification [30], and nuclease S1 digestion in the
presence of a labeled 93-residue oligodeoxyribonucleotide
[29, 31] (corresponding to positions −18 to +75 of the
coding strand of the β-globin reporter gene of OVEC-LTR)
were followed by denaturing gel electrophoresis of the digests
and phospho-imaging of the gel (Figure 4). The in vitro
transcription experiments were performed in triplicate with
nearly identical results.
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Recognition helix
GKTKRPRFGKTKRPRVGQQSIEQL ENGKTKRPRFGKTKRPRY
R42
(a)
Recognition helix
R64
GPKKKRKVGGGKTKRPRFGKTKRPRVGQQSIEQLENGKTKRPRFGKTKRPRYGGRRRRRRRRRG
NLS of SV40 Arg9
large T Ag
(b)
Recognition helixPTD-5
Hairless bipartite NLS
MKRAGRRQRRTSKLMKR PKRGKTKRPRFGKTKRPRVGQQSIEQL ENGKTKRPRFGKTKRPRY
R62
(c)
G PKKKRKVGGRRRRRRRRRG
Arg9
C20
NLS of SV40
large T Ag
(d)
-AATTAAGAACTGCTGACATCGAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGC-
HIV-1 LTR −137 to −68
NF-κB binding sites
35
(e)
Competitor DNA
5 -AAGAACTGCTGACATCGAGCTTGCTGTGCAGGCGCTGGGCCAGGGAGGCGT-3 
(f)
Figure 1: Relevant peptide and DNA sequences. (a) 42-residue HIV-1 enhancer-binding peptide (R42) derived from the DNA-binding
domain of 434 repressor. The recognition helix in (a), (b), and (c) is underlined. (b) 64-residue HIV-1 enhancer-binding peptide obtained
through extension of R42 by the nuclear localization signal of SV40 large T antigen and nona-arginine (NLS and Arg9 underlined). (c) 62-
residue HIV-1 enhancer-binding peptide obtained through extension of R42 at the N-terminus by the bipartite nuclear localization signal
of Hairless (underlined) embracing protein transduction domain-5 (PTD-5, italics). (d) 20-residue control peptide containing only NLS of
SV40 large T antigen and Arg9 linked by two glycine residues (NLS and Arg9 underlined). (e) 70-bp HIV-1 LTR DNA comprising positions
−137 to−68. The two identical NF-κB-binding sequences (enhancers) are underlined. (f) 51-bp competitor DNA lacking the two enhancers,
otherwise it is largely identical with the 70-bp HIV-1 LTR DNA shown in (e).
1 2 3 4 5
Figure 2: Competitive band shift assays of the interactions of R64 with 32P-labeled HIV-1 LTR DNA (Figure 1(e)) in the presence of
increasing amounts of unlabeled competitor DNA (Figure 1(f)). Samples (20 μL each) were incubated in 50mM phosphate buffer, pH 7.4,
for 30min at 37◦C [21] and then submitted to polyacrylamide gel electrophoresis at 250V in 33mM Tris, 0.75mM EDTA, adjusted to pH
8.2 using boric acid. R64; lanes 1 to 4 (8 pmol each); competitor DNA; lanes 1 to 4 (1, 4.25, 8.5, 17 pmol, resp.); labeled enhancer-containing
DNA (target DNA); lanes 1 to 5 (200 fmol each).
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Figure 3: Footprint assay of the specificity of R64-HIV-1 enhancer binding. The two enhancer sequences are marked by vertical bars. Lanes
1 to 5 contained 1 pmol each of labeled HIV-1 LTR DNA (positions –118 to –67), which had been methylated by dimethyl sulfate and cleaved
by piperidine in lanes 2 to 5. Lanes 3 to 5 contained R64 (50, 100 and 200 pmol, resp.) and competitor DNA (200 pmol per lane). Lane 6,
G/A bands of Maxam-Gilbert sequencing [24] of the HIV-1 LTR DNA. G∗, hyporeactive G bases.
2.5. Analysis of the Intracellular Localization of R64. CHO-
K1 cells (∼105 cells) containing different concentrations of
R64 were incubated at 37◦C for 24 h. The cells were then
harvested and treated with low-salt lysis buffer (containing
20mM KCl) at 4◦C for 5 minutes. The cytosolic extract was
obtained by centrifugation. The pellet was incubated with
high-salt lysis buffer (containing 1.2MKCl) at 4◦C for 5min-
utes and sonicated for 2 minutes to give the nuclear extract.
Both extracts were analyzed by standard electrophoresis
[32] and Western blotting [33] and R64 was detected
colorimetrically after addition of polyclonal rabbit anti-R42
antibodies, incubation with goat anti-rabbit IgG-conjugated
alkaline phosphatase, and addition of nitrotetrazolium blue
chloride and the p-toluidine salt of the 5-bromo-4-chloro-3-
indolyl phosphate substrate (Sigma) [13, 34] (Figure 5). The
experiment to study the intracellular localization of R64 was
performed twice with almost identical results.
2.6. Incubation of R64 (Figure 1(b)) and R42 (Figure 1(a))
with Phorbol-12-Myristate-13-Acetate (PMA)-Stimulated
CEM-GFP Cells. CEM-GFP cells [35] contain a plasmid
encoding a green fluorescent protein (GFP) reporter gene
under HIV-1 LTR control. Both HIV-1 and PMA stimulate
HIV-1 enhancer-linked transcription via activation of NF-κB
resulting in high level expression of GFP [36, 37]. CEM-GFP
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Figure 4: Gel electrophoretic analysis of the effect of R64 on in vitro transcription of OVEC-LTR and Sp1-OVEC in HeLa cell nuclear extract
(OVEC-LTR: target plasmid containing the two enhancer sequences of HIV-1 LTR and a β-globin reporter gene; Sp1-OVEC: control plasmid
lacking the enhancer sequences and the first 19 bp of the β-globin reporter gene). Transcription experiments containing the two plasmids,
100 ng each, and increasing amounts of R64 were performed as described in [14]. The total volume per experiment was 25 μL. Transcripts
were hybridized with a labeled synthetic 93-mer DNA, corresponding to positions –18 to +75 of the β-globin reporter gene and then treated
with nuclease S1. The resulting digests were submitted to gel electrophoresis in Tris-borate (89mM, pH 7.5), EDTA (2mM), urea (7M). The
gel shows the undigested RNA/DNA hybrids obtained. Lane 1: Sp1-OVEC; lanes 2 to 6: OVEC-LTR + Sp1-OVEC in the presence of 0, 16,
32, 65 and 97.5 pmol of R64, respectively.
Figure 5: Western blot of cytosolic and nuclear extracts of R64-containing CHO-K1 cells. R64 was detected using rabbit anti-R42 antiserum,
alkaline phosphatase-conjugated goat anti-rabbit IgG, and the phosphatase substrate 5-bromo-4-chloro-3-indolyl phosphate. Lane 1:
molecular mass markers; lane 2: synthetic R64 (calculated molecular mass, 7611Da; 500 ng applied); lanes 3 and 7: nuclear and cytosolic cell
extract controls; nuclear and cytosolic extracts of cells incubated with 1.3 μM R64 (lanes 4 and 8), 1.7 μM R64 (lanes 5 and 9), and 2.3 μM
R64 (lanes 6 and 10), respectively.
cells were maintained in 2mL RPMI-1640 medium supple-
mented with 100U/mL penicillin, 100 μg/ml streptomycin,
200mM L-glutamine, 24mM sodium bicarbonate, and 10%
heat-inactivated fetal calf serum (Life Technologies) in a
24-well culture plate for 24 h. Then PMA (200 ng per mL)
and increasing amounts of peptides R64 or R42 were added
per well and the change of fluorescence was observed in a
Nikon Diaphot 300 fluorescence microscope using a 485 nm
excitation filter and a 535 nm emission filter (Figure 6).
After 48 h, cell growth-inhibitory effects of the peptides
and PMA were assessed using the 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) assay [38].
2.7. Incubation of Peptides R64, R62, R42, and C20 with
HIV-1-Infected CEM-GFP Cells. R62 differed from R64 only
in the arrangement of the membrane transduction signals;
R62 (Figure 1(c)) contained both the nuclear localization
signal (NLS) and the plasmamembrane protein transduction
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Figure 6: Fluorescence microscopy of CEM-GFP cells. (a) unstimulated cells; (b) CEM-GFP cells stimulated with 0.32 μM PMA for 16 h at
37◦C; (c, d, e) CEM-GFP cells stimulated with 0.32 μM PMA in the presence of 4 μM, 8 μM, and 12 μM R42, respectively, for 6 h at 37◦C;
(f, g, h) treatment of CEM-GFP cells with 0.32 μM PMA in the presence of 2.6 μM, 5.25 μM and 7.9 μM R64, respectively, for 6 h at 37◦C
drastically reduced the number of cells expressing the GFP gene; the arrows point to representative cells in which the GFP gene was silenced.
domain (PTD) at the N-terminus of the peptide chain. C20
(Figure 1(d)), a 20-residue control peptide, comprised the
NLS and PTD sequences of R64, linked by two glycine
residues.
HIV-1 stocks were prepared from cultures of human H9
lymphoblastoid cells (NIH AIDS Research and Reference
Reagent Program) maintained in complete medium (RPMI-
1640 supplemented with 2mM L-glutamine, 24mM sodium
bicarbonate, and 10% heat-inactivated fetal calf serum (Life
Technologies)) and chronically infected with HIV-1 strain
III B (HIV-1IIIB). HIV-1-containing supernatant was filtered
through a 0.2 μm filter, aliquoted, and stored at −70◦C until
used.
Human CEM-GFP cells were in an exponential growth
phase before being pelleted in 50mL conical tubes (Falcon)
to give ∼ 9.6× 106 cells per tube.
Stocks of HIV-1IIIB obtained from the supernatant of
human H9 T cells were diluted 1 : 5 with complete medium,
a concentration previously determined to give a continuous
rate of HIV replication (data not shown). The CEM-GFP
cell pellets were incubated with 1-ml aliquots of diluted
HIV-1 and gently resuspended. After incubation at 37◦C for
2 h, excess virus was removed and the cells were thoroughly
washed with RPMI-1640 medium.
Cells were suspended in 48mL of complete medium
at a concentration of 2 × 105 cells per mL, and 2-ml
aliquots of either HIV-1-infected or mock-infected cells were
transferred to a 24-well Falcon tissue culture plate thus
containing 4 × 105 cells per well. The peptides R64, R62,
R42, and C20 were added in duplicate to the wells at final
concentrations of 0, 0.1, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5,
and 7 μM, respectively.
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At different time points, the HIV-1 p24 core protein
in the cell-free culture supernatants of the wells was deter-
mined by quantitative ELISA as described previously [10].
Briefly, duplicate supernatants (25 μL each) of the cultures
of the HIV-1-infected, peptide-treated CEM-GFP cells were
diluted 1 : 6 with buffer and then added to microplate wells
precoated with a mouse monoclonal anti-p24 antibody.
This was followed by addition of a biotinylated human
polyclonal anti-p24 antibody and incubation with strepta-
vidin-horseradish peroxidase conjugate. Additional binding
sites for streptavidin-horseradish peroxidase, created by
treating the wells with biotinyl-tyramide [40], were reacted
with a dilute solution of streptavidin-horseradish peroxidase
as recommended by the manufacturer. Finally, the o-
phenylene diamine substrate was added and the resulting
yellow color measured spectrophotometrically at 490 nm.
p24 was quantified by comparing the absorbances of the
samples with those of a standard curve obtained from p24
concentrations between 0.17 pg/mL and 10 ng/mL.
To determine the HIV-1 RNA levels in the culture super-
natants, quantitative real-time RT-PCRs specific for the gag
region of HIV-1 were performed as described in [41] using
1 μL of cell-free culture supernatant derived from the HIV-
1-infected, peptide-treated CEM-GFP cells, or 1 μL of an
RNA standard dilution series obtained from the supernatant
of HIV-1IIIB-infected human H9 lymphoblastoid cells and
calibrated using the Amplicor (Roche) quantitative RT-PCR
assay.
After eight days of incubation of the HIV-1-infected
cells with peptides, possible peptide-derived cytotoxic effects
were assessed using the MTT assay [38] with the following
modifications. The infected CEM-GFP cells grown in the
presence or absence of peptide were resuspended, duplicate
100 μL aliquots transferred to a 96-well ELISA plate (Nunc),
and 10 μL of a solution of 5mg MTT per mL PBS added
to each well. After a four-hour incubation, 100-μL solu-
bilization solution (10% SDS, 0.5% Triton X-100, 0.01M
HCl) was added per well and the plate further incubated
at 37◦C overnight. Finally the absorption was measured in
an ELISA plate reader (TecScan) at 570 nm with background
subtraction at 630 nm.
3. Results and Discussion
We have shown earlier that a 42-residue peptide derived from
the DNA-binding domain of bacteriophage 434 repressor
bound specifically to the enhancer region of HIV-1 long
terminal repeat and repressed the in vitro transcription of
HIV-1 enhancer-containing plasmids [14]. In the present
work we have demonstrated that this peptide was active in
HIV-1-infected cells after it had been extended by a protein
transduction domain to cross the plasma membrane and by
a nuclear localization signal to enter the nucleus. The best
results were obtained with peptide R64 (Figure 1(b)).
3.1. DNA Binding Specificity of R64 and R62 at the Two HIV-1
LTRNF-κB Binding Sites. The binding specificity of R64 and
R62 was determined by competitive band shift and footprint
assays. Band shift assays in the presence of R64 (Figure 2)
showed that, in the experimental conditions chosen, an
approximately 100-fold molar excess of competitor DNA
(Figure 1(f)) was required to displace the peptide from the
enhancer-containing HIV-1 LTR target DNA (Figure 1(e)).
The result of the band shift assay performed in the
presence of R62 was very similar (data not shown).
Footprint analysis followed a procedure [42] in which
protein-DNA complexes and free DNA were first separated
by band shift electrophoresis and then treated with a DNA-
cleaving reagent in the gel matrix. The resulting DNA
fragments were eluted from the gel and resolved by gel
electrophoresis. In the present work, the electrophoretically
separated bands of an R64-HIV-1 LTR DNA complex and
free HIV-1 LTR DNA were excised from the gel and the
DNA in the bands was treated with dimethyl sulfate, eluted
from the gel slices, and then incubated with piperidine
[24, 28]. The DNA fragments obtained were separated by
electrophoresis on a sequencing gel (Figure 3). The results
showed that the G bases of the two NF-κB binding sites
(enhancers, marked by vertical bars) of HIV-1 LTR were
largely protected from methylation in the presence of R64
(Figure 3, lanes 3 to 5) indicating that R64, like R42 [26],
could compete with NF-κB for HIV-1 enhancer binding
and thus inhibit enhancer-controlled transcription. This was
confirmed by the following experiments.
3.2. In Vitro Transcription Suppression. In HeLa cell nuclear
extracts, R64 suppressed the transcription of a reporter gene
from an HIV-1 enhancer-containing plasmid (OVEC-LTR)
more strongly than the transcription of this gene from a
control plasmid lacking the HIV-1 enhancer region (Sp1-
OVEC) [14, 29] (Figure 4, lanes 5 and 6). R62, largely iden-
tical with R64 except that an N-terminal bipartite nuclear
localization signal [43] embraces the protein transduction
domain (Figure 1(c)), was less specific in the suppression of
HIV-1 enhancer-controlled transcription than R64 despite
its lower net positive charge (+25 versus +28, data not
shown).
3.3. Analysis of the Intracellular Localization of R64. R64 was
shown to be present in both the cytosolic and nuclear extract
of R64-incubated CHO-K1 cells using a double antibody
assay following electrophoresis and Western blotting of
the two extracts (Figure 5). R64 was detected when its
concentration in the incubation mixture (∼105 cells/3mL
medium) was above 1.3 μM. The minute increase in the
amount of R64 in the nuclear extracts going from 1.7 μM to
2.3 μM R64 in the incubation mixtures (Figure 5, lanes 5 and
6) indicated that the “receptor” for nuclear protein import
[44] was almost saturated at 1.7 μM R64 in the incubation
mixture and that excess intracellular R64 remained in the
cytosol (Figure 5, lanes 9 and 10).
3.4. R64 Suppressed PMA-Stimulated HIV-1 Enhancer-Con-
trolled Transcription. After R64 was shown to be present
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Figure 7: Assessment of HIV-1 p24 levels in the culture supernatants of HIV-infected CEM-GFP cells during eight days of incubation with
increasing concentrations of peptides R64 (a), R62 (b), R42 (c), and C20 (d) starting at day one post-infection. The figure shows the results
of two independent in vitro infection experiments with mean value ± standard deviation.
in the nuclear extract of R64-incubated CHO-K1 cells
(Figure 5), it was tested whether this peptide was active in
intact CEM-GFP cells [35] which contain an HIV-1 LTR-
controlled GFP reporter gene whose expression is stimulated,
via activation of NF-κB, by HIV-1, TNF-α, interleukin-1,
lipopolysaccharide, and PMA [36, 37, 45].
CEM-GFP cells (approximately 105 cells in two mL
medium per well) were incubated with PMA (200 ng), which
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Figure 8: Determination of the 50% effective dose of peptide R64 based on R64 concentration-dependent HIV-1 p24 levels. Using the
CalcuSyn 1.1 software package (Biosoft) [39], a median-effect plot was derived from the dose-effect curve obtained at day 8 after infection
using the equation: fa/ fu = (D/Dm)m where D is the dose, Dm is the dose required for a 50% effect, fa is the fraction affected by the dose, fu
is the unaffected fraction, m is a coefficient of the sigmoidicity of the dose-effect curve, and r is the correlation coefficient (Dm = 0.493μM,
r = 0.6849, m = −0.981).
mimicked HIV-1 infection, and increasing amounts (20 to
60 μg) of R42 and R64, respectively. Fluorescence microscopy
showed that, in the experimental conditions applied, PMA
stimulated GFP gene expression strongly (Figures 6(a) and
6(b)). Addition of R42 lacking the plasma membrane trans-
duction and the nuclear localization signals of R64 had very
little if any effect on the fluorescence of the PMA-stimulated
CEM-GFP cells up to a concentration of 6 μM (Figures 6(c),
6(d) and 6(e)). R64, however, extinguished the fluorescence
of these cells almost completely at a concentration of
approximately 4 μM (Figures 6(f), 6(g) and 6(h)) because
it was able to enter the nucleus and to inhibit the HIV-1
enhancer-controlled expression of the GFP reporter gene.
Cytotoxicity in the presence of PMA and increasing
concentrations of R42 and R64 was not observed using the
MTT assay [38].
3.5. R64 Inhibited HIV-1 Replication in CEM-GFP Cells. R64
inhibited the HIV-1 replication in infected CEM-GFP cells in
a concentration-dependent manner as shown by quantitative
assays of HIV-1 p24 and HIV-1 gag RNA.
The HIV-1 p24 ELISA was performed as described [10].
In Figure 7, the results obtained with R64, R62 (Figure 1(c)),
R42 (Figure 1(a)), and C20 (Figure 1(d), comprising only
the nuclear and the plasma membrane transduction signals
of R64) are compared. Noticeable p24 production in the
presence of 0–7 μM R64 (Figure 7(a)) started approximately
six days after addition of the peptide except in the samples
containing 3.5 and 7 μM R64, respectively, in which HIV-1
p24 levels remained close to zero. The production of p24 in
the presence of 0–7 μMR62, R42, and C20 (Figures 7(b), 7(c)
and 7(d)) started uniformly after approximately five days of
incubation and then rose logarithmically without efficient
inhibition by these peptides.
Real-time RT-PCR experiments [41] showed that the
number of HIV-1 RNA copies permL supernatant of infected
cells dropped by nearly three orders of magnitude in the
presence of 7 μM R64 (Figure 9(a)) but remained constantly
high in the presence of 7 μMR62, R42 or C20 in the infection
experiments (Figures 9(b), 9(c) and 9(d)). At maximal
concentration of R64, HIV-1 replication was inhibited more
than 300-fold.
Figure 9 also indicates the degree of growth inhibition
of the HIV-1-infected CEM-GFP cells in the presence of
R64, R62, R42 and C20, respectively. The MTT assay used
for this purpose measures metabolically active, viable cells.
The maximum of 20% inhibition observed in the presence
of R64 (Figure 9(a)) indicates that 80% of the cells are still
metabolically active and viable. A loss of only 20% of the
metabolic capacity of these cells cannot account for more
than 300-fold inhibition of HIV-1 replication observed with
R64.
R62, which differed from R64 only in sequence and
arrangement of the nuclear localization and plasma mem-
brane transduction signals, had no antiviral activity in HIV-
1-infected CEM-GFP cells. From earlier work we knew that
R42 was not able to pass the plasma membrane and there-
fore was inactive in these assays. C20 presumably reached
the nucleus but its sequence did not have enhancer-binding
specificity.
In Figures 8 and 10, by using the CalcuSyn 1.1 (Biosoft)
software package [39], median-effect plots were derived
from dose-effect curves obtained for R64 as antiretroviral
compound using the median-effect equation:
fa/ fu = (D/Dm)m, (1)
where D is the dose, Dm is the dose required for a 50% effect,
fa is the fraction affected by the dose, fu is the unaffected
fraction and m is a coefficient of the sigmoidicity of the
dose-effect curve. The median-effect dose (Dm) was used to
describe the 50% effective dose (ED50) and in this case, this
ED50 corresponds to IC50 (50% inhibitory concentration)
which is the drug level needed to block 50% of HIV’s normal
replication in vitro.
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Figure 9: Assessment of HIV-1 RNA levels () and cell growth-inhibitory activity (•) in the culture supernatants of CEM-GFP cells at day
eight after infection with HIV-1 and incubation with increasing concentrations of peptides R64 (a), R62 (b), R42 (c), and C20 (d). Peptides
were added at day one after infection, their concentrations ranged from 0.1 μM to 7 μM. Growth inhibition was assessed using the MTT
assay. The figure shows the results of two independent in vitro infection experiments with mean value ± standard deviation.
R64 peptide titrations of HIV-1-infected CEM-GFP cells
analyzed by p24 ELISA and one tube real-time RT-PCR,
showed a 50% inhibitory R64 concentration between 0.588
and 0.493 μM, respectively.
In summary, based on previous work [14, 15, 18, 26],
we have designed a 64-residue peptide (R64, Figure 1(b))
containing a central HIV-1 enhancer recognition helix
and terminal nuclear localization and plasma membrane
transduction signals. This peptide bound to the two HIV-
1 enhancers and thus competed with NF-κB, the major
activator of HIV-1 replication [46, 47]. After incubation of
CHO-K1 cells with R64, the peptide could be localized to
cytosol and nucleus of these cells. In CEM-GFP cells, it
suppressed the HIV-1 enhancer-driven expression of the GFP
gene after PMA stimulation and inhibited viral transcription
and replication after HIV-1 infection in a concentration-
dependent manner. Most likely, R64 displaced NF-κB from
its two binding sites in HIV-1 LTR despite the presence of
NF-κB binding sites onmany cellular genes [48]. An artificial
62-residue peptide (R62, Figure 1(c)) which contained both
membrane transduction signals at the N-terminus but
otherwise was identical with R64, also bound to the HIV-1
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Figure 10: Determination of the 50% effective dose of peptide R64 based on R64 concentration-dependent HIV-1 RNA levels. Using the
CalcuSyn 1.1 software package (Biosoft) [39], a median-effect plot was derived from the dose-effect curve obtained at day 8 after infection
using the equation: fa/ fu = (D/Dm)m where D is the dose, Dm is the dose required for a 50% effect, fa is the fraction affected by the dose, fu
is the unaffected fraction, m is a coefficient of the sigmoidicity of the dose-effect curve, and r is the correlation coefficient (Dm = 0.588μM,
r = 0.8249, m = −1.320).
LTR enhancer region. However, it was active only in a cell-
free in vitro transcription assay and did not inhibit HIV-1
replication in infected cells.
Therapeutic peptides have important applications in
human diseases such as prevention of HIV-1 infection [2, 3],
induction of tumor-specific cytotoxic T-lymphocytes [17],
and as therapeutic vaccines [49]. R64 seemed to fulfil some of
the requirements as a therapeutic peptide: the Western blots
of the cytosolic and nuclear extracts of R64-incubated CHO-
K1 cells (Figure 5) showed no fragments, indicating stability
of the peptide against intracellular proteolytic degradation;
R64 reduced the viral replication by almost three orders of
magnitude and was not cytotoxic at a concentration of 7 μM
in the medium of HIV-1-infected CEM-GFP cells (Figure 9);
and uptake of R64 into cells appeared to be fast (Figure 6),
lowering the immunogenic potential of this peptide.
Abbreviations
HIV-1: Human immunodeficiency virus type 1
LTR: Long terminal repeat
R42: Artificial 42-residue HIV-1
enhancer-binding peptide
NLS: Nuclear localization signal
PTD: Protein transduction domain
GFP: Green fluorescent protein
NF-κB: Nuclear factor κB
Sp1: Specificity protein 1
PMA: Phorbol-12-myristate-13-acetate
MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide.
Bp: Base pair.
Acknowledgments
The authors dedicate this paper to the memory of Professor
R. B. Merrifield who invented the solid phase synthesis
of peptides. They thank Dr. Z. Tomasik for experimental
assistance, Professor W. Schaffner for OVEC plasmids, Dr.
F. Bootz for preparing anti-R42 antiserum, and the Kanton
of Zu¨rich and the Mesta Foundation for generous financial
support.
References
[1] G. Kalkut, “Antiretroviral therapy: an update for the non-
AIDS specialist,” Current Opinion in Oncology, vol. 17, no. 5,
pp. 479–484, 2005.
[2] C. T. Wild, D. C. Shugars, T. K. Greenwell, C. B. McDanal, and
T. J. Matthews, “Peptides corresponding to a predictive alpha-
helical domain of human immunodeficiency virus type 1 gp41
are potent inhibitors of virus infection,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 91, no. 21, pp. 9770–9774, 1994.
[3] J. M. Kilby, S. Hopkins, T. M. Venetta et al., “Potent
suppression of HIV-1 replication in humans by T-20, a peptide
inhibitor of gp41-mediated virus entry,” Nature Medicine, vol.
4, no. 11, pp. 1302–1307, 1998.
[4] S. Rao, S. Hu, L. McHugh et al., “Toward a live microbial
microbicide for HIV: commensal bacteria secreting an HIV
fusion inhibitor peptide,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 102, no. 34, pp.
11993–11998, 2005.
[5] D. M. Eckert and P. S. Kim, “Design of potent inhibitors of
HIV-1 entry from the gp41 N-peptide region,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 98, no. 20, pp. 11187–11192, 2001.
[6] E. Bianchi, M. Finotto, P. Ingallinella et al., “Covalent
stabilization of coiled coils of the HIV gp41 N region yields
extremely potent and broad inhibitors of viral infection,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 36, pp. 12903–12908, 2005.
[7] K. Babaahmady, W. Oehlmann, M. Singh, and T. Lehner,
“Inhibition of human immunodeficiency virus type 1 infec-
tion of human CD4+ T cells by microbial HSP70 and the
peptide epitope 407–426,” Journal of Virology, vol. 81, no. 7,
pp. 3354–3360, 2007.
12 Advances in Virology
[8] M. D. Miller, R. Geleziunas, E. Bianchi et al., “A human
monoclonal antibody neutralizes diverse HIV-1 isolates by
binding a critical gp41 epitope,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 102,
no. 41, pp. 14759–14764, 2005.
[9] R. S. Veazey, P. J. Klasse, S. M. Schader et al., “Protection of
macaques from vaginal SHIV challenge by vaginally delivered
inhibitors of virus-cell fusion,” Nature, vol. 438, no. 7064, pp.
99–102, 2005.
[10] J. Schu¨pbach, M. Flepp, D. Pontelli, Z. Tomasik, R. Lu¨thy,
and J. Bo¨ni, “Heat-mediated immune complex dissociation
and enzyme-linked immunosorbent assay signal amplification
render p24 antigen detection in plasma as sensitive as HIV-1
RNA detection by polymerase chain reaction,” AIDS, vol. 10,
no. 10, pp. 1085–1090, 1996.
[11] B. L. Levine, L. M. Humeau, J. Boyer et al., “Gene transfer
in humans using a conditionally replicating lentiviral vector,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 103, no. 46, pp. 17372–17377, 2006.
[12] L. Reynolds, C. Ullman, M. Moore et al., “Repression of the
HIV-1 5′ LTR promoter and inhibition of HIV-1 replication by
using engineered zinc-finger transcription factors,” Proceed-
ings of the National Academy of Sciences of the United States
of America, vol. 100, no. 4, pp. 1615–1620, 2003.
[13] M. Oufir, Artificial HIV-1 enhancer binding peptides fused with
nuclear localization signals and protein transduction domains as
passive repressors of HIV-1 LTR-controlled transcription, Ph.D.
thesis, Universita¨t Zu¨rich, Zu¨rich, Switzerland, 2004.
[14] G. Caderas, S. Klauser, N. Liu, A. Bienz, and B. Gutte, “Inhibi-
tion of HIV-1 enhancer-controlled transcription by artificial
enhancer-binding peptides derived from bacteriophage 434
repressor,” European Journal of Biochemistry, vol. 266, no. 2,
pp. 599–607, 1999.
[15] T. Hehlgans, M. Stolz, S. Klauser et al., “The DNA-binding
properties of an artificial 42-residue polypeptide derived from
a natural repressor,” FEBS Letters, vol. 315, no. 1, pp. 51–55,
1993.
[16] W. Arap, W. Haedicke, M. Bernasconi et al., “Targeting
the prostate for destruction through a vascular address,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 3, pp. 1527–1531, 2002.
[17] Y. Oka, A. Tsuboi, T. Taguchi et al., “Induction of WT1
(Wilms’ tumor gene)-specific cytotoxic T lymphocytes by
WT1 peptide vaccine and the resultant cancer regression,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 101, no. 38, pp. 13885–13890, 2004.
[18] P. A. Wender, D. J. Mitchell, K. Pattabiraman, E. T. Pelkey,
L. Steinman, and J. B. Rothbard, “The design, synthesis, and
evaluation ofmolecules that enable or enhance cellular uptake:
peptoid molecular transporters,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 97, no.
24, pp. 13003–13008, 2000.
[19] B. U. Samuel, B. Hearn, D. Mack et al., “Delivery of antimi-
crobials into parasites,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 100, no. 2, pp.
14281–14286, 2003.
[20] V. Pande andM. J. Ramos, “Nuclear factor kappa B: a potential
target for anti-HIV chemotherapy,” Current Medicinal Chem-
istry, vol. 10, no. 16, pp. 1603–1615, 2003.
[21] M. Fried and D. M. Crothers, “Equilibria and kinetics of
lac repressor-operator interactions by polyacrylamide gel
electrophoresis,” Nucleic Acids Research, vol. 9, no. 23, pp.
6505–6525, 1981.
[22] R. B. Merrifield, “Solid phase peptide synthesis. I. The
synthesis of a tetrapeptide,” Journal of the American Chemical
Society, vol. 85, no. 14, pp. 2149–2154, 1963.
[23] R. B. Merrifield, “Solid-phase peptide synthesis,” in Peptides-
Synthesis, Structures and Applications, B. Gutte, Ed., pp. 93–
169, Academic Press, San Diego, Calif, USA, 1995.
[24] A. M. Maxam and W. Gilbert, “Sequencing end-labeled DNA
with base-specific chemical cleavages,” Methods in Enzymol-
ogy, vol. 65, pp. 499–560, 1980.
[25] M.M. Garner and A. Revzin, “A gel electrophoresis method for
quantifying the binding of proteins to specific DNA regions:
application to components of the Escherichia coli lactose
operon regulatory system,” Nucleic Acids Research, vol. 9, no.
13, pp. 3047–3060, 1981.
[26] K. Sta¨dler, N. Liu, L. Trotman et al., “Design, synthesis,
and characterization of HIV-1 enhancer-binding polypeptides
derived from bacteriophage 434 repressor,” International Jour-
nal of Peptide and Protein Research, vol. 46, no. 3-4, pp. 333–
340, 1995.
[27] D. J. Galas and A. Schmitz, “DNAse footprinting: a simple
method for the detection of protein-DNA binding specificity,”
Nucleic Acids Research, vol. 5, no. 9, pp. 3157–3170, 1978.
[28] N. Liu, Artificial HIV-1 enhancer-binding peptide dimerized by
a leucine zipper and study of a retro-leucine zipper, Ph.D. thesis,
Universita¨t Zu¨rich, Zu¨rich, Switzerland, 1999.
[29] G. Westin, T. Gerster, M. M. Mu¨ller, G. Schaffner, and W.
Schaffner, “OVEC, a versatile system to study transcription
in mammalian cells and cell-free extracts,” Nucleic Acids
Research, vol. 15, no. 17, pp. 6787–6798, 1987.
[30] E. Schreiber, P. Matthias, M. M. Mu¨ller, and W. Schaffner,
“Rapid detection of octamer binding proteins with “mini-
extracts”, prepared from a small number of cells,”Nucleic Acids
Research, vol. 17, no. 15, p. 6419, 1989.
[31] R. F. Weaver and C. Weissmann, “Mapping of RNA by a
modification of the berk-sharp procedure: the 5′ termini of
15 S beta-globin mRNA precursor and mature 10 S beta-
globin mRNA have identical map coordinates,” Nucleic Acids
Research, vol. 7, no. 5, pp. 1175–1194, 1979.
[32] H. Scha¨gger and G. von Jagow, “Tricine-sodium dodecyl
sulfate-polyacrylamide gel electrophoresis for the separation
of proteins in the range from 1 to 100 kDa,” Analytical
Biochemistry, vol. 166, no. 2, pp. 368–379, 1987.
[33] H. Towbin, T. Staehelin, and J. Gordon, “Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
sheets: procedure and some applications,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 76, no. 9, pp. 4350–4354, 1979.
[34] J. McGadey, “A tetrazolium method for non-specific alkaline
phosphatase,” Histochemie, vol. 23, no. 2, pp. 180–184, 1970.
[35] A. Gervaix, D. West, L. M. Leoni, D. D. Richman, F. Wong-
Staal, and J. Corbeil, “A new reporter cell line to monitor HIV
infection and drug susceptibility in vitro,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 94, no. 9, pp. 4653–4658, 1997.
[36] Y. Li, G. Mak, and B. R. Franza Jr., “In vitro study of functional
involvement of Sp1, NF-kappa B/Rel, and AP1 in phorbol
12-myristate 13-acetate-mediated HIV-1 long terminal repeat
activation,” Journal of Biological Chemistry, vol. 269, no. 48, pp.
30616–30619, 1994.
[37] D. Thanos and T. Maniatis, “NF-kappa B: a lesson in family
values,” Cell, vol. 80, no. 4, pp. 529–532, 1995.
[38] T. Mosmann, “Rapid colorimetric assay for cellular growth
and survival: application to proliferation and cytotoxicity
Advances in Virology 13
assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp.
55–63, 1983.
[39] T.-C. Chou and M. Hayball, CalcuSyn for Windows 3.1 and 95:
Multiple Dose Effect Analyzer andManual for IBM-PC, Biosoft,
Cambridge, UK, 1996.
[40] M. N. Bobrow, T. D. Harris, K. J. Shaughnessy, and G.
J. Litt, “Catalyzed reporter deposition, a novel method of
signal amplification. Application to immunoassays,” Journal of
Immunological Methods, vol. 125, no. 1-2, pp. 279–285, 1989.
[41] L. R. Bisset, S. Bosbach, Z. Tomasik, H. Lutz, J. Schu¨pbach, and
J. Bo¨ni, “Quantification of in vitro retroviral replication using
a one-tube real-time RT-PCR system incorporating direct
RNA preparation,” Journal of Virological Methods, vol. 91, no.
2, pp. 149–155, 2001.
[42] M. D. Kuwabara and D. S. Sigman, “Footprinting DNA-
protein complexes in situ following gel retardation assays
using 1,10-phenanthroline-copper ion: Escherichia coli RNA
polymerase-lac promoter complexes,” Biochemistry, vol. 26,
no. 23, pp. 7234–7238, 1987.
[43] K. Djabali, V. M. Aita, and A. M. Christiano, “Hairless is
translocated to the nucleus via a novel bipartite nuclear
localization signal and is associated with the nuclear matrix,”
Journal of Cell Science, vol. 114, no. 2, pp. 367–376, 2001.
[44] T. Tachibana, M. Hieda, and Y. Yoneda, “Up-regulation
of nuclear protein import by nuclear localization signal
sequences in living cells,” FEBS Letters, vol. 442, no. 2-3, pp.
235–240, 1999.
[45] A. S. Baldwin, “The NF-kappa B and I kappa B proteins: new
discoveries and insights,” Annual Review of Immunology, vol.
14, pp. 649–681, 1996.
[46] G. Nabel and D. Baltimore, “An inducible transcription factor
activates expression of human immunodeficiency virus in T
cells,” Nature, vol. 326, no. 6114, pp. 711–713, 1987.
[47] G. E. Griffin, K. Leung, T. M. Folks, S. Kunkel, and G. J.
Nabel, “Activation of HIV gene expression during monocyte
differentiation by induction of NF-kappa B,” Nature, vol. 339,
no. 6219, pp. 70–73, 1989.
[48] M. Grilli, J. J. S. Chiu, andM. J. Lenardo, “NF-kappa B and Rel:
participants in amultiform transcriptional regulatory system,”
International Review of Cytology, vol. 143, pp. 1–62, 1993.
[49] T. Jones, “Vacc-4x, a therapeutic vaccine comprised of four
engineered peptides for the potential treatment of HIV
infection,” Current Opinion in Investigational Drugs, vol. 11,
no. 8, pp. 964–970, 2010.
